Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Next revisionBoth sides next revision
home:diseases:aging [01.12.2019] – [Read more] sallieqhome:diseases:aging [01.26.2019] – [Aging (senescence)] sallieq
Line 8: Line 8:
  
  [[https://immunityageing.biomedcentral.com/articles/10.1186/1742-4933-3-12/comments|Recovery from some of the diseases of aging]]  [[https://immunityageing.biomedcentral.com/articles/10.1186/1742-4933-3-12/comments|Recovery from some of the diseases of aging]]
 +
 +Inflammation, But Not Telomere Length, Predicts Successful Ageing at Extreme Old Age: A Longitudinal Study of Semi-supercentenarians.    (({{pubmed>long:26629551}})) 
  
 Health of the hypothalamus may be a controlling factor as demonstrated in a mouse study by Yalin Zhang et al <blockquote> Mechanistically, hypothalamic stem/progenitor cells contributed greatly to exosomal microRNAs (miRNAs) in the cerebrospinal fluid, and these exosomal miRNAs declined during ageing, whereas central treatment with healthy hypothalamic stem/progenitor cell-secreted exosomes led to the slowing of ageing.  [[http://www.nature.com/nature/journal/vaop/ncurrent/full/nature23282.html|Hypothalamic stem cells control ageing speed partly through exosomal miRNAs]] Health of the hypothalamus may be a controlling factor as demonstrated in a mouse study by Yalin Zhang et al <blockquote> Mechanistically, hypothalamic stem/progenitor cells contributed greatly to exosomal microRNAs (miRNAs) in the cerebrospinal fluid, and these exosomal miRNAs declined during ageing, whereas central treatment with healthy hypothalamic stem/progenitor cell-secreted exosomes led to the slowing of ageing.  [[http://www.nature.com/nature/journal/vaop/ncurrent/full/nature23282.html|Hypothalamic stem cells control ageing speed partly through exosomal miRNAs]]
Line 32: Line 34:
   * **Cellular theory** – According to this theory, the normal body has a finite potential to replicate and maintain functional capacity (Hayflick limit).   * **Cellular theory** – According to this theory, the normal body has a finite potential to replicate and maintain functional capacity (Hayflick limit).
  
 +==== Breaking up defunct cells ====
  
 +[[https://www.ebiomedicine.com/article/S2352-3964(18)30629-7/fulltext|Article in Press
 +Senolytics in idiopathic pulmonary fibrosis]]  
 +<blockquote>
 + Selectively ablating senescent cells using dasatinib plus quercetin (DQ) alleviates IPF-related dysfunction in bleomycin-administered mice.
 +
 +Our first-in-humans open-label pilot supports study feasibility and provides initial evidence that senolytics may alleviate physical dysfunction in IPF  (({{pubmed>long:30616998}})).</blockquote>
 ===== Diseases of the aging are chronic diseases ===== ===== Diseases of the aging are chronic diseases =====
  
Line 119: Line 128:
  
  
 +===== Recent research =====
 +
 +Cell membranes are primarily made up of two types of lipids — phospholipids and glycolipids. Inside cells, these lipids bind to a molecule called CD1d that transports them to the surface. Once there, phospholipids stimulate phospholipid-reactive T cells, and glycolipids stimulate a different type of T cell called iNKTs.
 +
 +On their way to the cell’s surface, phospholipids more easily attach themselves to CD1d molecules, making it more difficult for glycolipids to attach to CD1d. Because of this, it is harder for glycolipids to make it to the surface of the cell. This means that iNKTs cannot be as easily stimulated by glycolipids.
  
 +Scientists believe iNKT cells are necessary because they appear to protect cells against the progression of certain cancers and autoimmune diseases. However, iNKT cells are extremely active and can cause alcoholic hepatitis or other types of liver diseases if they are overstimulated. The phospholipid’s ability to more easily bind to CD1d molecules than glycolipids keeps a balance between the two cell types and maintains homeostasis in the immune system.   (({{pubmed>long:30508304}})) 
 ===== Read more ===== ===== Read more =====
  
Line 126: Line 141:
  
  
-==== summary of Olmesartan research on aging ====+==== summary of research into effects of Olmesartan ====
  
  
-[[home:food:aim_health:aging|Geriatric protective effects of Olmesartan]]+[[home:food:aim_health:aging|Protective effects of Olmesartan]]
  
  
Line 138: Line 153:
 ===== Notes and comments ===== ===== Notes and comments =====
    
 +//Lee// " I am 70 now (not 65) when we started this conversation ...lolDr's were amazed that I was in such good shape and all fractures were closed and healed well. I would like to say I may not bicycle ride now ..but it's a family thing and I probably will "
  
 +  (({{pubmed>long:000}})) 
 +  
 <DiseaseHierarchy> <DiseaseHierarchy>
  
home/diseases/aging.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.